← Search & browse all drugs
DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Imidazole and triazole derivatives
tiabendazole
D01AC06
Forms & Strengths
- Oral suspension: 500 mg/5 mL
- Chewable tablet: 500 mg
- Topical formulation: 10% (historical/regional)
Adult Dosing
- Strongyloidiasis: 25 mg/kg orally twice daily for 2 days (max 3 g/day)
- Cutaneous larva migrans: 25 mg/kg orally twice daily for 2 to 4 days
- Visceral larva migrans: 25 mg/kg orally twice daily for 7 days
- Trichinosis: 25 mg/kg orally twice daily for 2 to 4 days
Pediatric Dosing
- Children > 15 kg: 25 mg/kg orally twice daily (same duration as adult indications)
- Safety and efficacy in infants and children weighing less than 15 kg have not been established
Indications
- Treatment of strongyloidiasis (threadworm)
- Treatment of cutaneous larva migrans (creeping eruption)
- Treatment of visceral larva migrans
- Treatment of trichinosis (during the invasive phase)
Mechanism of Action
- Inhibits the helminth-specific enzyme fumarate reductase
- Interferes with microtubule polymerization by binding to beta-tubulin, disrupting cellular function and viability in susceptible nematodes
Contraindications
- Hypersensitivity to thiabendazole or any component of the formulation
- Co-administration with theophylline (risk of elevated theophylline toxicity)
Adverse Reactions
- Nausea, vomiting, anorexia, diarrhea, abdominal pain
- Dizziness, drowsiness, headache, fatigue
- Pruritus, rash, erythema multiforme, Stevens-Johnson syndrome (rare)
- Transient rise in liver enzymes, cholestatic jaundice
- Leukopenia, malodor of urine, crystalluria
Drug Interactions
- Theophylline: Thiabendazole significantly inhibits CYP1A2, decreasing the clearance of theophylline and increasing risk of severe toxicity
- Hepatotoxic drugs: Concomitant use may increase the risk of liver injury
Curated Content: Needs Vetting Before Put to Clinical Use